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Stroke is one of the leading causes of death in the
United States and also in other developed countries.
Carotid endarterectomy (CEA) is the gold standard
treatment to reduce stroke risk in patients with sig-
nificant carotid occlusive disease, the results of
which have been documented with multicenter, ran-
domized controlled trials.1-5 However, CEA has
limitations, and various complications, such as peri-
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Objective: Although percutaneous angioplasty and stenting (PTAS) of carotid bifurcation
lesions is feasible and appropriate for surgically inaccessible lesions, its general role and
comparative value remain unclarified. Moreover, the acceptance of carotid PTAS has been
limited by its potential for producing embolic debris. This study used an ex vivo model to
evaluate the efficacy of a novel filter device to entrap emboli during PTAS of human
carotid plaques.
Methods: Eight carotid bifurcation plaques were obtained from patients who underwent
carotid endarterectomy for high-grade atherosclerotic stenosis (>90%). The mean age of
the patients was 63 years, and six patients were symptomatic. Each plaque was encased
with polytetrafluoroethylene material to simulate adventitia and was connected to a per-
fusion circuit, which provided continuous flow through the plaque. The filter device con-
sisted of an expandable polymeric membrane with multiple micro pores that was attached
to the distal end of a 0.014-in wire with a shapeable tip. This filter was encased in a deliv-
ery catheter. With fluoroscopic guidance, the filter wire was passed through the stenosis
and the delivery catheter was then retracted to open the filter to capture particles released
into the distal internal carotid artery. PTAS with a self-expandable stent then was carried
out over the filter wire. The particles released during the initial filter passage, those cap-
tured in the filter, and those that flowed through or around the filter (missed) were col-
lected and analyzed with light microscopy.
Results: Filter deployment, PTAS, and filter retrieval were achieved successfully with
each lesion. Because the filter has a low crossing profile, it passed through the stenoses
smoothly and only produced occasional small particles. PTAS improved the angio-
graphic stenosis from 96.2% ± 3.7% to 1.3% ± 1.6%. The mean number and the maxi-
mum size of the particles that were released during initial filter passage, missed, and cap-
tured by the filter device were 3.1 and 500 m m, 2.8 and 360 m m, 20.1 and 1100 m m,
respectively. Most of the particles and those of large size were released during PTAS. The
filter captured 88% of these particles.
Conclusion: These study results show that this filter device, at least in this model, did not
add complexity to the interventional procedure itself. Furthermore, the filter may
markedly decrease embolic events during carotid PTAS and expand the indications for
this procedure. (J Vasc Surg 1999;30:1034-44.)
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operative myocardial infarction, stroke, cranial nerve
injury, and wound problems, have been reported at
rates ranging between 12% and 21%.1-5
Carotid angioplasty and stenting (CAS) has
recently emerged as an alternative to CEA. Although
good results have been reported from several cen-
ters,6-13 concerns regarding the safety and efficacy of
CAS have been raised, and its general role and com-
parative value remain unclear.14-19 Among the vari-
ous concerns, the potential of CAS to produce
embolic particles that may manifest as a neurologic
deficit has been a major concern.14,15,20
One potential solution to prevent embolic events
is the use of a filter placed distal to the site of inter-
vention that can capture and retrieve these embolic
particles. This study was undertaken to determine
the feasibility and efficacy of such a device with our
ex vivo human carotid stenting model.
MATERIALS AND METHODS
Preparation of the carotid specimen. The ex
vivo model used for this study has previously been
described in detail.20 In brief, human carotid plaque
specimens (n = 8) were obtained from patients who
underwent standard CEA procedures for clinically
significant carotid bifurcation stenoses. Because the
purpose of this study was to evaluate the efficacy of
a filter device in capturing embolic particles and
because we have previously shown that the number
of embolic particles correlated with the degree of
stenosis, only those plaques with a stenosis > 90%
were used (Table I).20 Endarterectomy specimens
were removed as “casts” of the carotid bifurcation
vessels, devoid only of the adventitia, and were kept
circumferentially intact (Fig 1A). The excised speci-
mens were encased in an expanded polytetrafluo-
roethylene (PTFE) wrap to recreate a structural
adventitia (Fig 1B). In an effort to recreate the dis-
tal internal carotid artery, a 5-mm expanded PTFE
graft then was attached to the distal end of the inter-
nal carotid artery portion. The proximal end of the
specimen was connected to the inside of a radiolu-
cent plastic bath (Fig 2). A bag containing isotonic
saline solution was positioned 130 cm above the
bath and connected to the proximal end of the spec-
imen so that continuous saline solution flow could
be maintained through the lumen of the specimen
during the entire endovascular procedure. The distal
internal carotid artery (5-mm PTFE graft) was con-
nected to the effluent port of the bath so that the
effluent could be filtered and any embolic particles
could be captured. In addition, to create a closed
circuit, the external carotid artery was suture ligated
with 5-0 sutures. A radiopaque ruler was placed
beside the specimens to allow accurate angiographic
measurements (Fig 3A).
Description of the cerebral protection device
and carotid angioplasty and stenting. The Med-
Nova NeuroShield device (Horsham, W Sussex,
United Kingdom) is a temporary percutaneous, trans-
luminal intra-arterial filtration system. It is designed
to conform to the vessel lumen and to capture emboli
produced during CAS while maintaining flow (Fig 4).
The filtration element is mounted 2 cm proximal
from the distal tip of the 0.014-in guidewire and has
large entry ports at the proximal end and multiple
perfusion ports at the distal end. The filtration ele-
ment contains a preshaped nitinol expansion system
that assists in filter deployment and in visualization
with fluoroscopy. The system consists of a delivery
catheter, a filter guidewire, and a retrieval catheter
(Fig 5). The filter guidewire, which is encapsulated in
the delivery catheter, was introduced through the
main port of the sheath that was connected to the
plaque. This filter guidewire was passed through the
stenosed carotid plaque, after which the delivery
catheter was retracted, thereby deploying the filter in
the distal internal carotid artery (Fig 3B,C). The
delivery catheter then was withdrawn completely and
discarded. The maintenance of flow through the filter
was evaluated with the injection of contrast. A 4 ·
40–mm coronary angioplasty balloon (SCIMED,
Minneapolis, Minn) then was inserted over this filter
guidewire to the target lesion (Fig 3D). After predi-
latation, an 8 · 20–mm Wallstent (Medi-tech Corp,
Watertown, Mass) was deployed across the lesion (Fig
3E). A 5 · 20–mm balloon was inflated again at 
10 atm to ensure the complete deployment of the
Wallstent, and a completion angiogram was then
obtained (Fig 3F). After the completion of the pro-
cedure, the filter guidewire was recovered with a
retrieval catheter. The filtration element along with
any captured embolic particle was completely
enveloped with the introduction of the large bore
retrieval catheter over the wire, and the entire device
and its contents then were removed.
Collection and analysis of embolic particles. A
continuous flow of saline solution was maintained
through the specimen throughout all the endovascu-
lar procedures, and the effluent was filtered (130 m m)
to analyze the embolic particles. This filter that was
connected to the effluent port (Fig 2) was exchanged
to a second filter, after initial filter guidewire passage
and flushing, to separately analyze the embolic parti-
cles generated during this period. After MedNova fil-
ter deployment, a new filter was connected to the
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Table I. Characteristics of the carotid plaque and the embolic particles
Percent stenosis No. of particles (maximum size; m m)
Specimen Pre CAS Post CAS Initial* Missed Captured Total
1 95 2 2 (120) 1 (140) 20 (720) 23
2 90 2 2 (150) 1 (150) 6 (400) 9
3 99 0 3 (150) 4 (250) 1 (400) 8
4 99 1 3 (500) 1 (200) 11 (720) 15
5 90 0 0 (0) 1 (120) 10 (400) 11
6 95 1 7 (300) 10 (360) 28 (1100) 45
7 95 5 6 (360) 3 (120) 75 (720) 84
8 99 1 2 (140) 1 (150) 9 (600) 12
Average 96.2 1.3
Total 25 22 160 207
Average 3.1 2.8 20.0 25.9
SD 2.3 3.2 23.7 26.4
Percent of total 12.0 10.6 77.4 100
Percent of CAS† 12.1 87.9 100
*Particles released during initial filter guidewire passage.
†Percent of particles released during angioplasty and stenting.
CAS, Carotid angioplasty and stenting.
Fig 1. A, Human carotid plaque specimen. Specimens were removed as plaque casts of carotid
bifurcation and were kept circumferentially intact. i, Internal carotid artery; e, external carotid
artery; c, common carotid artery; s, superior thyroid artery. B, Expanded polytetrafluoroethylene
(ePTFE) wrapped specimen. Distal half of ePTFE graft is cut longitudinally, and plaque is insert-
ed into graft. Redundant ePTFE material covering internal carotid plaque portion is trimmed 
and sutured (s). With permission from Ohki T, Marin ML, Lyon RT, Berdejo GL, Ohki M,
Soundararajan K, et al. Human ex vivo carotid artery bifurcation stenting: correlation of lesion
characteristics with embolic potential. J Vasc Surg 1998;27:463-71.
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effluent port to analyze the particles that flowed
through or around the filter guidewire (missed parti-
cles). The continuous flow of saline solution was
maintained for 5 minutes after stent deployment, and
the plaque was flushed with saline solution before the
retrieval of the filter guidewire to assure that any
loose particles adherent to the plaque were recov-
ered. The number, size, and composition of the
recovered embolic particles were analyzed with a dis-
secting microscope at 70 · magnification (SMZ-U,
Nikon, Tokyo, Japan).
RESULTS
Because the filter guidewire was encapsulated in a
small profile delivery catheter, the initial filter passage
was accomplished in all the cases without any difficul-
ty. Flow through the filter guidewire after deployment
was not compromised as assessed with contrast injec-
tion (Fig 3F). CAS was performed successfully with fil-
ter guidewire protection in all the cases. After
Wallstent deployment, the degree of stenosis improved
from 96.2% ± 3.7% to 1.3% ± 1.6% (Fig 3A,F; Table
I). The retrieval catheter was inserted over the filter
guidewire, and all the embolic particles were recovered
without difficulty. The number and size of the particles
released during initial filter passage (Fig 6), those cap-
tured in the filter guidewire (Fig 7A,B), and those that
flowed through or around the filter (missed; Fig 8) are
shown in Fig 9. The mean number and the maximum
size of the particles that were released during initial fil-
ter passage, those that were missed, and those that
were captured by the filter device were 3.1 and 500
m m, 2.8 and 360 m m, and 20.0 and 1100 m m, respec-
tively (Table I). Most of the particles and those of large
size were released during PTAS, and the filter captured
88% of these particles.
These particles were composed predominantly of
atherosclerotic debris and some organized thrombus
and calcified material (Figs 6 to 9). The mean size
(±SD) of the overall particles was 226.5 ± 130.7 m m,
and the mean number (±SD) was 26 ± 26.
DISCUSSION
Although angioplasty for carotid bifurcation steno-
sis has been performed since 1983, it received little
attention until stent technology was developed and
applied.21,22 Stent placement has greatly improved the
early anatomic results of angioplasty, regardless of the
anatomic location of the atherosclerosis, by providing
a greater immediate gain in luminal diameter, repairing
dissections, and providing a smoother, potentially less
thrombogenic luminal surface. Since stents have been
used to improve the results of carotid angioplasty, CAS
has been performed more widely by various investiga-
tors with mixed results.13-16,23,24 Because there is no
level 1 or 2 evidence regarding the comparative effica-
cy of CAS and CEA, attempts to draw any firm con-
clusions, either positive or negative, regarding CAS are
premature.
There are several reasons why CAS has not gained
wide spread acceptance, including the potential for
CAS to release emboli, the lack of an ideal dedicated
stent, the questionable efficacy of CAS in the preven-
tion of stroke, the expected difficulties in cases in
which CEA is required for restenosis, and the
unknown long-term durability. Nevertheless, much
work is being done in the field of CAS, and several
recent reports have begun to address some of the pre-
viously mentioned concerns. Several new, dedicated
carotid stents are already in clinical trials. Various
investigators have reported that restenosis after CAS is
rare and ranges between 3% and 5% at 6 months.6 In
addition, Liu et al25 have published their preliminary
results in an abstract form, which suggest that CAS
may show long-term efficacy in the prevention of the
future occurrence of ipsilateral strokes. The feasibility
and relative ease of performing a CEA after stent
placement have also been reported.26,27 Despite these
Fig 2. Schematic drawing of ex vivo apparatus and bath.
Expanded polytetrafluoroethylene covered plaque (CP) is
connected to custom-made sheath. This plaque-sheath
complex is connected to main port of bath. Saline solution
bag raised to 130 cm above the bath is connected to flush
channel of main port to maintain continuous flow through
lumen of specimen (arrows). Sheath with three-way valve
at proximal end is inserted into center channel of main
port, which allows insertion of various endovascular imag-
ing and interventional devices. Effluent is drained through
a filter to collect embolic particles generated during
endovascular procedure. Orifice of external carotid artery
(ECA) is ligated to maintain closed circuit. 
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advances, the potential of CAS to release emboli and
cause neurologic damage has yet to be addressed, and
this remains the most important issue regarding this
therapy.
Because of the complex nature of carotid plaques
that may be fibrous, calcific, necrotic, or hemor-
rhagic, there is no animal model that mimics human
carotid bifurcation, atherosclerotic lesions.28
Therefore, in this study, we used clinically significant
carotid plaques obtained during CEA to mimic the
scenario in patients as much as possible. In these
experiments, we reconfirmed that, at least in this
model, each CAS produces a certain amount of
embolic particles.
Fig 3. A, Preinterventional ex vivo angiogram. High-grade stenosis is seen in internal carotid
artery. External carotid artery (e) is ligated. r, Radiopaque ruler. B, Initial filter guidewire pas-
sage through stenosis was accomplished without difficulty, owing to low profile and smooth
transition between tip wire and delivery catheter. f, Nitinol-supported filter encased in delivery
catheter before deployment. C, Fluoroscopic image after filter guidewire deployment. Nitinol-
supported filter (f) is fully deployed in distal internal carotid artery. D, Predilatation of lesion
is performed with a coronary balloon under filter protection. E, Wallstent is also deployed
under filter protection. F, Completion angiogram shows successful recanalization of internal
carotid artery. Flow through filter is preserved. a, Air emboli captured in filter.
A B C
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The MedNova filter was effective both in the
recanalization of the tight stenoses (mean, 95.3%)
and in the capturing of most of the particles. As a
result of its flexible wire tip, its low crossing profile,
and the smooth transition between the tip guidewire
and the filter, the crossing of even the tightest
lesions (preocclusive) was accomplished without dif-
ficulty, although some particles were released during
initial guidewire and filter passage. The particles that
were released were relatively few and small in diam-
Fig 4. Drawing of MedNova NeuroShield (Horsham, W
Sussex, United Kingdom). Filter guidewire is initially
encased in low-profile delivery catheter (d). After delivery
catheter retrieval, filter (f) is completely deployed. w, 0.014-
in shapeable guidewire; b, bullet providing smooth transition
between wire and delivery catheter.
Fig 5. MedNova NeuroShield (Horsham, W Sussex,
United Kingdom). Filtration element has large entry ports
at proximal end and multiple perfusion ports (p) at distal
end. Filtration element contains pre-shaped nitinol (n)
expansion system that assists in filter deployment and in
visualization under fluoroscopy. e, Embolic particles.
Fig 6. Microscopic view of embolic particles released during initial filter guidewire passage.
Three small particles consisting of atherosclerotic debris were recovered (filter size, 130 m m;
original magnification, · 40).
JOURNAL OF VASCULAR SURGERY
1040 Ohki et al December 1999
eter as compared with those released during balloon
dilatation and stenting. The particles that were
released during filter guidewire passage may not
have been caused by its character and could have
been associated with any guidewire passages. Markus
et al29 have studied the sequence of embolization
during CAS by means of a transcranial Doppler
scan.15 They also found that the vast majority of the
particles were released during angioplasty and stent-
ing. However, with standard coronary wires, they
also observed small amounts of embolic particles
generated during initial guidewire passage. In addi-
tion, the crossing profile of the filter guidewire is not
greater than a low profile coronary balloon, which
must be placed across the lesion even if a filter is not
used. It is probable that a few small embolic particles
are well tolerated by the brain because such emboli
have also been observed during CEA. They
appeared to be of no clinical significance if the num-
ber were small.30-32
Fig 7. A, Close-up view of inside of filter guidewire after carotid artery stenting. Multiple
embolic particles have been captured in filter. n, Nitinol frame. B, Microscopic view of embol-
ic particles captured by filter guidewire. These particles consisted of organized thrombus and
atheroscrelotic debris (filter size, 130 m; original magnification, · 40).
A
B
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Our data also show that the filter guidewire
missed some embolic particles (12%). Most of these
missed particles were those that were smaller than
the size of the pore in the filter. Although the num-
ber and the size of such particles were small, on the
basis of this observation, the pore size has been fur-
ther reduced in size. This modification will probably
reduce the number of these missed particles.
However, the size and the number of particles that
the brain can tolerate remains unknown—intuitively,
the less the better. Those particles that were missed
and that were larger than the filter pore size proba-
bly flowed around the filter or were released during
filter recovery with the retrieval catheter.
Ideally, all the embolic particles should be recov-
ered. However, of note was the fact that the use of
the filter guidewire did not add any significant com-
plexity to the interventional procedure, at least in
our model, which was designed to mimic the clinical
procedure. Our previous experience with this model
without a filter produced similar total numbers of
particles overall (24.5 ± 29.9).20 Therefore, any par-
ticles that were released and captured by the filter
(88%) represented a potential benefit of the filter
guidewire.
Although encouraging results were obtained from
this experiment, the efficacy of this filter guidewire
system must be ultimately proven in a clinical setting
because this model does not completely mimic the
clinical setting. These limitations include the fact that
the plaques had been excised from patients, had been
covered with PTFE materials, and had lacked pulsatile
flow.20 If this device proves to be effective in the
retrieval of particles and the reduction of the stroke
rate associated with CAS without adding importantly
to the complexity of the procedure itself, as was the
case in our study, it should resolve the major remain-
ing issue that is preventing the wide spread acceptance
of CAS by lowering the peri-interventional stroke
rate. In addition, its use will be especially valuable for
Fig 9. Size and number of embolic particles released dur-
ing initial filter passage, those captured by filter, and those
missed by filter. 
Fig 8. Microscopic view of embolic particles that were missed by filter guidewire. 
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physicians who are inexperienced with CAS, and it
may be possible to reduce the morbidity associated
with their initial learning period. Furthermore, this
filter device has the potential to be of benefit in the
interventional treatment of other lesions, in which
distal embolization is also a concern, such as degener-
ated saphenous vein grafts and renal artery stenosis.
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Dr Kenneth Ouriel (Cleveland, Ohio). It is my privi-
lege to be the opening discussant for this intriguing paper
by Dr Ohki and the Montefiore group and Dr Roubin and
his group at Lenox Hill.
I should mention that I, too, am a consultant for some
of these companies, in particular three companies that are
working on developing filters either for the carotid arter-
ies or the periphery.
Carotid stenting is a procedure that, as recently as 1
year ago, most vascular surgeons would have dismissed as
impractical and illogical. For decades, we have been taught
that carotid bifurcation disease produces symptoms as a
result of embolization from an irregular cholesterol and
sometimes thrombus-laden plaque. We have learned that
the hemodynamic compromise of a critical lesion is only
rarely responsible for symptoms. To the contrary, it is only
the association between the degree of stenosis and the
complexity of the plaque that accounts for the direct cor-
relation between percent stenosis and the risk of subse-
quent neurologic events.
Thus, none of us who spent the greater parts of our
careers carefully plucking microscopic shreds of media from
the surface of an endarterectomized carotid artery would
have predicted that carotid stenting would achieve the results
that it has. We would not have guessed that the placement of
an uncovered stent across a critical carotid lesion, a tech-
nique that may rid the bifurcation of its stenosis but surely
does little to alter the irregular surface of the plaque, would
be associated with something less than uniform failure.
And yet, carotid stenting has achieved clinical
equipoise with carotid endarterectomy. As evidence for
this, we now know that both the National Institutes of
Health and the Food and Drug Administration are willing
to execute a large randomized trial comparing carotid
stenting and endarterectomy. But like any other interven-
tion, be it open or percutaneous, pitfalls arise. And in the
absence of restenosis, the Achilles’ heel of carotid stenting
may be the occurrence of distal embolization during the
manipulation of the plaque. Dr Ohki and his colleagues
should be congratulated for their tenacity in the develop-
ment of a model to study this phenomenon. It is only
through the use of such clinically relevant models that
antiembolic devices can be appropriately designed, tested,
redesigned, and retested. The data presented today sug-
gest that the MedNova device (Horsham, W Sussex,
United Kingdom) holds potential as an efficient means of
trapping emboli released during carotid stenting. But no
model can be without flaws, and in this regard there are a
few drawbacks to Dr Ohki’s system on which I would like
him to comment.
First, the model uses carotid plaque removed at the
time of endarterectomy, which has been transected at the
proximal and distal margins, exposing a shelf of subintimal
material that is thickest proximally—and if Dr Ohki is the
technician I believe him to be—thinnest distally. Does this
factor artifactually increase the release of debris from a
defect in the arterial surface that would otherwise not have
been exposed? In other words, can subintimal debris be
extruded from within and beneath the plaque in a manner
not dissimilar to squeezing a tube of toothpaste that has
the cap off and a hole on the crimped end?
Second, I have misgivings about the choice of pore size
in the filter used to quantify the embolized debris. The
approximate size of an important intracerebral artery may
be as small as 100 m m. Only clinical experience will reveal
whether the choice of a 300-m m pore size for the MedNova
device is appropriate. And this is not my present worry. I am
concerned, however, that the 130-m m filter used to collect
and quantify those emboli missed by the MedNova device
has, in fact, missed potentially a large number of particles in
the range of 100 m m, particles that could result in sympto-
matic cerebral infarction.
Short of these two minor criticisms, I believe that this
manuscript is the type of basic endeavor to which we
should all aspire. The authors’ work represents a carefully
designed and executed research project that results in
rapid transition of important information from the bench
to the bedside. Thank you.
Dr Takao Ohki. Dr Ouriel, thank you for your thor-
ough review and nice comments. I think you have three
questions. The first one was regarding to the deficit or the
flaws of the model. And that was related to the fact that
the external surface of the plaque was exposed, and there-
by there is the potential of particles being released from
the outside surface rather than the inside, which would
not be present in a clinical setting. In this particular
model, because we added the distal extension, we really
did not have the opportunity to see when and how the
particles were released. But in our early experience, as I
showed in the videotape, the covering of the polytetraflu-
oroethylene only extended to the very distal portion of the
plaque. And every time we inflated a balloon or placed a
stent, we were monitoring with a video or a separate
observer was making sure when and where the particles
came from. And through that experience, I can assure you
that the majority, if not all, of the particles came from the
intraluminal and not the outside surface. So, that is the
best I can say about the model. But also I want you to
understand that there is no other model that can mimic
the clinical setting better than our model. So, I fully
acknowledge the weakness of the model. Nonetheless, I
believe that it is as close to the clinical setting as possible.
The next question was regarding the size of the filter.
In this particular study, we used a pore size of 300 m m,
and it did miss those particles smaller than this. And the
pore size of the second filter, which was to analyze the par-
ticles, was 130 m m. On the basis of this experiment, the
company has gone back and changed the size of the pore,
and now it is down to 100 m m. These pores are laser-pen-
etrated holes, and it is very easy to alter the size. However,
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the reduction of the size of the pore would also increase
the resistance of the blood flow and could cause potential
thrombosis. So, there is a trade off in making too fine of a
filter. I do believe that the model is not perfect and also
that this filter is not perfect, but I would like to mention
that we do not have to make a perfect filtration device
because currently there is nothing. And as long as you cap-
ture some particles, that is a potential benefit as compared
with nothing. So, even if we missed about 12% of the par-
ticles, whatever was recovered is of benefit.
Thank you very much.
Dr Robert E. Madden (Valhalla, NY). Do you have
any idea or do you intend to investigate what pressure gra-
dient might be created across this filter? That is the num-
ber one question.
And number two, what would you predict is going to
be the total time of placement in a clinical situation? How
long will this filter be in place?
Dr Takao Ohki. Very good questions. Because there
was no pressure in our model, I cannot really answer that
question. But the company has done animal work where
they placed the filter in a pig’s carotid artery. Although they
did not measure pressure, I have been informed that the
angiogram after filter placement showed very good flow. So,
although there might be some reduction in pressure or flow,
I believe that it is adequate to maintain the brain function.
But that ultimately has to be proven in a clinical setting,
especially in those with contralateral occlusions.
The total time that this filter is placed would highly
depend on the experience of the interventionist or the sur-
geon. When I observed Gary Roubin do this in ex vivo, I
would say it took somewhere around 10 to 15 minutes.
Dr Matthew J. Dougherty (Philadelphia, Pa). I
enjoyed your paper. And I have mixed feelings. Because
although it confirmed my bias against this procedure in
terms of what you are harvesting after a balloon dilatation,
it also addresses my main objections. So, now I have to
rethink things.
But my recollection from some of the transcranial
Doppler scan data was that a fair amount of emboli or par-
ticles were being released for 24 hours after the procedures.
How do you address that? I guess my concern is that after
you have done your balloon and you have done your stent,
where most of the emboli occur, you may still have a pret-
ty raggedy surface that may be embolizing for a period of
time thereafter. Do you have any way to address that?
Dr Takao Ohki. Very good point. It is true that on the
basis of the transcranial Doppler study that emboli is
released continuously for both carotid endarterectomy and
stents. But those numbers and the sizes of particles are sig-
nificantly lower than those compared with the number of
emboli and the size of emboli released during balloon infla-
tion/deflation.
In addition, on the basis of the clinical experience
from Nancy, Washington, and New York, we know that
most stroke always happens on the table. And once a
patient is off the table, almost nothing happens thereafter.
So, from the clinical experience and from the TCD expe-
rience, I believe that the critical point is during the proce-
dure. There might be some additional emboli released
after stenting, but that is also true for endarterectomy.
Dr Enrico Ascher (Brooklyn, NY). Dr Ohki, I very
much enjoyed your presentation.
I have a little bit of a concern regarding your comment
that it is a totally safe procedure. I cannot imagine any-
thing being 100% safe inside the arterial system, particu-
larly when there is nothing to protect above the filter. The
problem is: is the filter potentially harmful? Is there any
way that the filter can dissect the internal carotid artery
distal to the plaque when it opens? Can it raise a flap? Can
it create a clot above the basket? Is there any potential
complication that you have not seen yet because you have
not really applied it in humans? I just cannot believe that
it is a device that is 100% safe.
Dr Takao Ohki. I am sure that, like the stent grafts,
with any new procedure comes along a new complication.
Our model did not address those concerns that you just
mentioned: flap, clot, dissection. But we all know that the
distal carotid artery is relatively disease free, so the poten-
tial to dissect the distal carotid artery, in my view, I think
is small.
The issue regarding thrombosis of the filter is a real
one. The company has done a bunch of animal studies in
which they used miniature swine, which mimics human
nature in terms of thrombotic characteristics. And in that
model, they initially had some problem because of the
material, and then they changed the surface characteristics.
And now, they have not seen any fibrin deposition or
thrombosis. And also during carotid stenting, the patient is
fully anticoagulated. So, although it has to be proven in the
clinical setting, they are doing the right animal work, and I
think it is ready to test in humans. But you might be right.
